Ranolazine for the treatment of refractory angina in a veterans population.

Background: Pivotal ranolazine trials did not require optimization of conventional medical therapy including coronary revascularization and antianginal drug therapy prior to ranolazine use. This case series describes the use of ranolazine for the treatment of chronic stable angina refractory to maximal medical treatment in a veterans population.

Results: A total of 18 patients with a median age of 66 years were identified.